	Amplication No.	A	
	Application No.	Applicant(s)	
Notice of Allowability	09/972,834	LOEB ET AL.	_
	Examiner	Art Unit	
	Jeffrey Fredman	1637	_
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in) or other appropriate commu IGHTS. This application is si	this application. If not included nication will be mailed in due course. T	'HIS nitiative
1. This communication is responsive to <u>March 2, 2005</u> .			
2. The allowed claim(s) is/are <u>58-73</u> .			
3. \boxtimes The drawings filed on <u>04 October 2001</u> are accepted by the	e Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have Horizontal Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	e been received. e been received in Application	n No	the
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirement	s
5. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	nitted. Note the attached EXA es reason(s) why the oath or	MINER'S AMENDMENT or NOTICE O declaration is deficient.	F
6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date ldentifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the sheet of the state of the sheet of	son's Patent Drawing Review s Amendment / Comment or .84(c)) should be written on the	in the Office action of e drawings in the front (not the back) of R 1.121(d).	
 DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT 	sit of BIOLOGICAL MATE FOR THE DEPOSIT OF BIO	RIAL must be submitted. Note the LOGICAL MATERIAL.	
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Su Paper No./N 08), 7. ☑ Examiner's A	ormal Patent Application (PTO-152) mmary (PTO-413), Mail Date Amendment/Comment Statement of Reasons for Allowance	
		JEFFREY FREDMAN PRIMARY EXAMINER	

HU

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 09/972,834 Page 2

Art Unit: 1637

EXAMINER'S COMMENT

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 2, 2005 has been entered.

Election/Restrictions

2. Claim 58 is directed to an allowable product, since the species Arg660Lys is found allowable. Under Markush practice, the remaining species are hereby rejoined and were fully examined for patentability under 37 CFR 1.104.

Since all pending species and pending claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement made in the Office action mailed on July 23, 2002 is hereby withdrawn.

Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance: The claimed invention is drawn to Taq polymerase mutants with particular substitutions in the Taq polymerase sequence. The specification makes it clear what Taq polymerase is at page 6, noting that "Figure 1 shows the nucleotide and amino acid sequence of Taq DNA polymerase I (SEQ ID NOS:1 and 2, respectively)". The specification and figure 2 also make it clear that the mutations are found in SEQ ID NO: 2 at the specified

Application/Control Number: 09/972,834 Page 3

Art Unit: 1637

locations. The closest prior art reference, Suzuki et al, was removed with a 1.132 declaration. There is no other prior art which teaches or suggests any of the particular changes in the Taq polymerase sequence. A terminal disclaimer was filed to overcome the related patent, U.S. Patent 6,395,524, which claimed similar subject matter. Therefore, the claims are novel and unobvious over the cited prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance." Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jeffrey Fredman

JEFFREY FREDMAN PRIMARY EXAMINER